11 research outputs found

    Holistic Mission God’s Plan for God’s People

    Get PDF
    This volume on holistic mission addresses this challenge in a dynamic and multi-faceted way through a variety of voices from different contexts. Many should find the collection of materials it contains useful, stimulating and rewarding. Above all, as I commend it to you, may it stir greater response and engagement in the spread of the gospel of the kingdom of God throughout the world.https://scholar.csl.edu/edinburghcentenary/1008/thumbnail.jp

    Effective science teaching

    No full text
    127 p. : il.; 26 cm

    Lines of Sight : An Exhibition of Drawing by Six Artists of Prince Edward Island

    No full text
    Collected interviews, correspondence and statements trace the artists' relationship to the medium of drawing over the course of preparation for the exhibition. Biographical notes. 6 bibl. ref

    The marine compound and elongation factor 1A1 inhibitor, didemnin B, provides benefit in western diet-induced non-alcoholic fatty liver disease

    No full text
    Inhibition of eukaryotic elongation factor 1A1 (EEF1A1) with the marine compound didemnin B decreases lipotoxic HepG2 cell death in vitro and improves early stage non-alcoholic fatty liver disease (NAFLD) in young genetically obese mice. However, the effects of didemnin B on NAFLD in a model of long-term diet-induced obesity are not known. We investigated the effects of didemnin B on NAFLD severity and metabolic parameters in western diet-induced obese mice, and on the cell types that contribute to liver inflammation and fibrosis in vitro. Male 129S6 mice were fed either standard chow or western diet for 26 weeks, followed by intervention with didemnin B (50 μg/kg) or vehicle by intraperitoneal (i.p.) injection once every 3 days for 14 days. Didemnin B decreased liver and plasma triglycerides, improved oral glucose tolerance, and decreased NAFLD severity. Moreover, didemnin B moderately increased hepatic expression of genes involved in ER stress response (Perk, Chop), and fatty acid oxidation (Fgf21, Cpt1a). In vitro, didemnin B decreased THP-1 monocyte proliferation, disrupted THP-1 monocyte-macrophage differentiation, decreased THP-1 macrophage IL-1β secretion, and decreased hepatic stellate cell (HSteC) proliferation and collagen secretion under both basal and lipotoxic (high fatty acid) conditions. Thus, didemnin B improves hepatic steatosis, glucose tolerance, and blood lipids in obesity, in association with moderate, possibly hormetic, upregulation of pathways involved in cell stress response and energy balance in the liver. Furthermore, it decreases the activity of the cell types implicated in liver inflammation and fibrosis in vitro. These findings highlight the therapeutic potential of partial protein synthesis inhibition in the treatment of NAFLD
    corecore